Trevor S. Arnold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Trevor S. Arnold has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Cynthia C. Powell
Department of Clinical Sciences College of Veterinary Medicine Colorado State University 300 W. Drake Rd. Fort Collins CO 80523 USA
1 shared publicationLuke A. Wittenburg
Department of Clinical Sciences College of Veterinary Medicine Colorado State University 300 W. Drake Rd. Fort Collins CO 80523 USA
1 shared publication
Latest Publications
- 27 June 2013
- Published by Wiley in Veterinary Ophthalmology
- Vol. 17 (5) , 328-333
Effect of topical naltrexone 0.3% on corneal sensitivity and tear parameters in normal brachycephalic dogs
Objective: To determine the effect of topical naltrexone 0.3% on tear production, corneal sensitivity, and tear film stability in normal brachycephalic dogs.Animals Studied: Twenty‐two normal brachycephalic dogs.Procedures: Measurements of tear production (Schirmer tear test I andII), intraocular pressure (IOP), central corneal sensitivity (CS), and tear film breakup time (TFBUT) were collected at time 0, 1, and 24 h after administration of either naltrexone (NTX) 0.3% or placebo (SV). Naltrexone orSVwas then administered once daily for 1 week, and the above measurements were repeated at 7 days, then again 7 days after discontinuing medication. Owners scored the degree of comfort, redness, rubbing, squinting, and tearing. Serum was collected at time 0, 1, 24 h, and 7 days to determine systemic concentrations.Results: Owners reported no significant change in the degree of comfort, redness, rubbing, squinting, or tearing. Naltrexone was detected in serum of all treated dogs 1‐h postadministration (average: 908 pg/mL, range: 319–1570 pg/mL) and in two dogs at the 1‐week time point. Naltrexone was not detected at the 24‐h time point. There was no significant effect ofNTXonSTT1,STT2,IOP,CS, orTFBUT.Conclusions: Naltrexone 0.3% is well tolerated and safe when applied topically to the eye once daily. Naltrexone 0.3% did not show any significant effects on corneal parameters as measured in this study. At once, daily dosingNTXis systemically absorbed; however, the degree of systemic absorption is not likely to be clinically significant.
- 27 June 2013
- Published by Wiley in Veterinary Ophthalmology
- Vol. 17 (5) , 328-333
Effect of topical naltrexone 0.3% on corneal sensitivity and tear parameters in normal brachycephalic dogs
Objective: To determine the effect of topical naltrexone 0.3% on tear production, corneal sensitivity, and tear film stability in normal brachycephalic dogs.Animals Studied: Twenty‐two normal brachycephalic dogs.Procedures: Measurements of tear production (Schirmer tear test I andII), intraocular pressure (IOP), central corneal sensitivity (CS), and tear film breakup time (TFBUT) were collected at time 0, 1, and 24 h after administration of either naltrexone (NTX) 0.3% or placebo (SV). Naltrexone orSVwas then administered once daily for 1 week, and the above measurements were repeated at 7 days, then again 7 days after discontinuing medication. Owners scored the degree of comfort, redness, rubbing, squinting, and tearing. Serum was collected at time 0, 1, 24 h, and 7 days to determine systemic concentrations.Results: Owners reported no significant change in the degree of comfort, redness, rubbing, squinting, or tearing. Naltrexone was detected in serum of all treated dogs 1‐h postadministration (average: 908 pg/mL, range: 319–1570 pg/mL) and in two dogs at the 1‐week time point. Naltrexone was not detected at the 24‐h time point. There was no significant effect ofNTXonSTT1,STT2,IOP,CS, orTFBUT.Conclusions: Naltrexone 0.3% is well tolerated and safe when applied topically to the eye once daily. Naltrexone 0.3% did not show any significant effects on corneal parameters as measured in this study. At once, daily dosingNTXis systemically absorbed; however, the degree of systemic absorption is not likely to be clinically significant.